Asian Spectator


The Times

.

Razer Blade 2026 Laptop Lineup Compared: Blade 14 vs 16 vs 18

LOS ANGELES, USA - Media OutReach Newswire - 26 June 2026 - Razer Blade laptops have always been engineered for pure performance, and the 2026 lineup brings that into focus more than ever. Each chass...

OPPO Collaborates with Artist Julian Stanczak to Provide Aquamorphic Wallpaper in ColorOS 13

SHENZHEN, CHINA - Media OutReach - 8 September 2022 -Following the release of ColorOS 13, OPPO today unveils a new Aquamorphic Wallpaper[i] in collaboration with the estate of Op Art artist...

Omdia: Semiconductor market plateaus after five consecutive qu...

LONDON, June 23, 2022 /PRNewswire-AsiaNet/ -- The red-hot semiconductor market reached a plateau in the first quarter of 2022 after five straight quarters of record revenues on top of contin...

Berkeley Lights Launches Two New Capabilities in the Opto Cell...

EMERYVILLE, Calif., Apr. 28, 2020 /PRNewswire-AsiaNet/-- -- The new multiplex cytokine and cytotoxicity assays as a part of the Opto Cell Therapy Development 1.0 workflow will help users of ...

PRCA Thailand Conference Reveals Nine in Ten Thais Want Transparency as AI Use Explodes

BANGKOK, THAILAND - Media OutReach Newswire - 14 August 2025 – As Thailand accelerates investment in artificial intelligence (AI), new research from PRCA APAC and YouGov reveals that ...

APRINOIA Announces Approval from NMPA to Initiate Phase 3 Clin...

SUZHOU, China, Oct. 28, 2020 /PRNewswire-AsiaNet/ -- APRINOIA Therapeutics announced today that China National Medical Products Administration (NMPA) had approved to initiate Phase 3 clinica...

Seeing Machines' world-leading interior sensing technology on ...

CANBERRA, Australia, April 3, 2023 /PRNewswire-AsiaNet/ -- Seeing Machines Limited (AIM: SEE), the advanced computer vision technology company that designs AI-powered operator monitoring sys...

ElectrifAi Offers New Machine Learning Models for Amazon SageM...

JERSEY CITY, N.J., Nov. 11, 2020 /PRNewswire-AsiaNet/ -- -- Delivering fast and reliable machine learning business solutionsElectrifAi, one of the global leading companies in practical artif...

150 Scholarships to Empower Pathways to STEM Sustainability ...

NEW YORK, July 2, 2022 /PRNewswire-AsiaNet/ -- Empowering young people from diverse backgrounds across the globe is central to addressing global challenges like climate change. AFS Intercult...

Australian CRO Avance Clinical Designated an Essential Service as Strong Demand from Sponsors Continues Amid COVID-19 Crisis

Australian CRO Avance Clinical Designated an Essential Service as Strong Demand from Sponsors Continues Amid COVID-19 Crisis

Adelaide, AUS, Apr 9, 2020 - (ACN Newswire) - Leading Australian CRO Avance Clinical said there was still strong demand from Asian and US sponsors, and commended Australian sites that had risen to the challenge to deliver for Avance Clinical clients during this difficult time.

Australian CRO Avance Clinical Designated an Essential Service as Strong Demand from Sponsors Continues Amid COVID-19 Crisis

Avance Clinical is a medium-sized full-service CRO known for its nimble and collaborative approach, with more than 20-years of experience in managing early phase trials.

Avance Clinical's Chief Strategist Ben Edwards said a key factor in sponsor demand is the speed and attractive cost of running trials in Australia. In particular, they include:

- The Australian Government financial rebate of more than 40% on clinical trial spend- No IND required for clinical trials and streamlined regulatory processes- Advanced medical, research and scientific community, leading investigators and KOLs, and modern medical facilities

Watch video - how we work here https://www.avancecro.com/

Avance Clinical CEO Yvonne Lungershausen, who has a background in pure research, said sponsors saw the value of running studies in Australia.

"In addition, Australia is not as hard hit by the COVID-19 crisis which has meant we can work with sites to deliver studies that might otherwise be put on hold, costing time and money and causing crippling delays to drug pipelines," said Ms Lungershausen."We are pleased to be the Australian CRO of choice for international sponsors," she said.

"Australia's reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials."

For more information about the benefits of running your next study in Australia contact us: https://www.avancecro.com/contact-us/

About Avance Clinical

Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organisations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.

Avance Clinical offers high quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialised patient groups. Other benefits include:

1. The Government R&D grant means more than 40% rebate on clinical trial spend2. Telehealth pivot during COVID-19 pandemic - speed and continuity3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks4. No IND required for clinical trials5. Full GMP material is not mandated for Phase I clinical trials6. Established clinical trial environment with world-class Investigators and sites7. Established healthy subject databases and specialised patient populations8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care9. Major hospitals with world class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons.

Media Contact: media@avancecro.comChris Thompson

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Common Risks Hidden in Commercial Lease Agreements

Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

Why Early Protection of Intellectual Assets is Critical

For many businesses, intellectual assets are among the most valuable things they own, yet they're often the last to receive formal legal protection. A brand name or a proprietary process can represe...

hacklink hack forum hacklink film izle hacklink z-libraryGrandpashabetGrandpashabetholiganbet giriş爱思助手下载telegram下载jojobet girişgrandpashabetgrandpashabet twiter xbetparktelegram webbetasus girişcasibomjojobetbetasusslot sitelerispincoagen bolagrandpashabetgrandpashabetjojobetholiganbetcasibom